Key Highlights
- Bodycote (LSE:BOY) shares rocketed roughly 23% to close at about 923p on 5 August 2026 after confirming competing cash approaches from CVC and Veritas Capital.
- CVC has proposed up to 915p per share and Veritas up to 914p per share, implying an equity value of roughly £1.56bn-£1.6bn.
- Both bidders face a 'put up or shut up' deadline of 5pm on 2 September 2026 to announce a firm offer or walk away.
- This is Bodycote's second brush with a bidder in 2026 after Apollo Global Management withdrew an approach at around 885p a share in June.
- Bodycote's 2025 full-year results showed revenue down 4% to £727.1m and adjusted operating profit down 11.4% to £114.3m, yet the board still launched an £80m buyback.
Two rival buyout houses, CVC and Veritas Capital, have tabled competing cash approaches for the FTSE 250 heat-treatment group, sending its shares up more than 23 per cent and reviving the well-worn debate about London's undervalued engineers.
A two-horse race breaks cover
For once, the phrase "bidding war" is not journalistic licence. On Wednesday 5 August Bodycote, the Macclesfield-based thermal-processing specialist, confirmed that it had received competing preliminary cash proposals from two of private equity's larger names. The statement, issued under Rule 2.4 of the Takeover Code, followed what the company called "recent media speculation regarding a possible offer".
The response from investors was emphatic: Bodycote shares rocketed roughly 23 per cent on the day, closing at about 923p and lifting the group back into the takeover spotlight it briefly occupied earlier this year. Tellingly, that closing price sits above both indicative offers, a sign the market is betting the contest is not yet finished.
Two important caveats belong up front. Neither suitor has made a firm offer under Rule 2.7, so this remains a possible-offer situation rather than a completed deal. And the headline "£1.8bn" refers to Bodycote's enterprise value including net debt; the equity proposals themselves value the company at closer to £1.6bn.
From Macclesfield to the FTSE 250
Bodycote is not a household name, but it is a genuine niche champion. It describes itself as "the world's largest and most recognised provider of advanced heat treatment and specialised metallurgical technologies", running around 150 facilities across more than 20 countries. Its furnaces harden, coat and strengthen metal components for customers in aerospace, defence, energy and automotive — sectors where a failed part is not an option.
That profile makes the group a classic private-equity target: asset-heavy, deeply embedded in customer supply chains, exposed to structurally growing aerospace and defence demand, and — crucially — cheaply rated in sterling terms relative to US and continental peers.
The numbers on the table
- The two proposals are strikingly close. According to Bodycote's announcement:
- CVC has proposed a value of up to 915p per share, comprising 907.8p in cash plus a permitted 7.2p interim dividend.
- Veritas Capital has proposed up to 914p per share — 906.8p in cash plus the same 7.2p dividend.
- With 170,221,102 shares in issue, CVC's terms imply an equity value of roughly £1.56bn. Both bidders have been granted access to confirmatory due diligence, and Bodycote's board said it "would be minded to recommend unanimously" either proposal to shareholders should it be firmed up. The company is being advised by Barclays and Goldman Sachs, with Herbert Smith Freehills Kramer as legal counsel.
- Under Rule 2.6, both CVC and Veritas face a "put up or shut up" deadline of 5pm on 2 September 2026 to announce a firm intention to bid or walk away, unless the Takeover Panel grants an extension.
The financial backdrop
The suitors are pouncing after a softer trading year. Bodycote's 2025 full-year results showed revenue of £727.1m, down about 4 per cent, and adjusted operating profit of £114.3m, down 11.4 per cent, as the adjusted operating margin slipped to 15.7 per cent from 17.0 per cent. Automotive and general industrial markets were weak, partly offset by accelerating aerospace and defence demand. The dividend was held at 23.0p, and management launched an £80m share buyback — hardly the posture of a board that expected to be fielding buyout approaches within months.
What it means for shareholders and staff
For long-suffering holders, the approaches crystallise value that the public market had not. At 915p, CVC's terms represent a healthy uplift on where the shares traded before bid speculation took hold, and comfortably above levels seen through much of the past year.
Yet the fact that the shares closed above both indicative prices suggests some investors expect a knock-out bid nearer, or beyond, the top of the range. Income and tracker funds that have held Bodycote for its dependable dividend now face a familiar dilemma: bank a cash premium, or lose a rare UK-listed industrial compounder to private hands. For staff and sites, new private-equity ownership typically brings a sharper focus on cash generation and capital allocation.
A wider hunt for UK engineers
Bodycote's plight is emblematic of a broader theme. Overseas buyers and buyout funds have spent recent years picking off London-listed engineers and industrials whose valuations lag international comparables — a discount frequently blamed on the City's shrinking pool of natural buyers for mid-cap manufacturing.
This is also Bodycote's second brush with a bidder in 2026. According to reports, US firm Apollo Global Management came close to a deal at around 885p a share — roughly £1.5bn — before withdrawing its approach in June. That the company has drawn three separate suitors inside a year underscores just how coveted its franchise has become, and how persistently the public market has underpriced it.
The risks and unknowns
Several things could still derail a clean outcome. First, no firm offer yet exists; either party could withdraw before the 2 September deadline, as Apollo did in June, which would likely see the share-price premium unwind sharply. Second, the two bids are effectively level-pegging, raising the prospect that one or both must raise terms to prevail — or that neither does. Third, a deal of this size in aerospace and defence-adjacent metallurgy could attract regulatory and national-security scrutiny in the UK, US and elsewhere, given the sensitivity of Bodycote's customer base.
What to watch
The immediate signpost is the 2 September deadline. Watch for any move to a firm Rule 2.7 offer, for either bidder to sweeten its terms, and for the board to convert its "minded to recommend" language into a formal recommendation. A third party — trade or financial — gate-crashing the auction cannot be ruled out, nor can a competition or foreign-investment review that lengthens the timetable. Should both suitors walk, Bodycote would be left to make its own case for a valuation the market has, so far, been unwilling to grant. For now, the auction is live, the premium is real, and the outcome is anything but settled.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...